CGCN GROUP, LLC
Lobbying for EMERGENT BIOSOLUTIONS INC. · Biopharmaceutical Company
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025.